

2. The following information is based on my knowledge of West's customary and routine business practices during the time I have been employed.
3. West obtains news articles under license from Business Wire for inclusion on Westlaw to permit authorized subscribers to access these articles.
4. West includes the text of the news articles on Westlaw as they are received from Business Wire.
5. The three articles attached to this affidavit are accurate copies of the articles as they appear on Westlaw as of today's date.
6. These three articles, to the best of my knowledge and belief, would have been available to authorized Westlaw subscribers as of the following times:
 - a. Business Wire article titled "BG-12 Psoriasis Study Meets Primary Endpoint; Oral Compound Also Being Studied for MS in Phase II Trial" was available on April 7, 2005 at 07:15:03 a.m. CT.
 - b. Business Wire article titled "Phase II Study of Oral Compound BG-12 Meets Primary Endpoint in Multiple Sclerosis" was available on January 9, 2006 at 07:49:24 a.m. CT.
 - c. Business Wire article titled "Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis; Treatment with BG-12 Led to Statistically Significant Reductions in MRI measures" was available on May 30, 2006 at 09:13:05 a.m. CT.

I affirm that the statements contained herein are known by me or believed by me to be true and correct.

7/3/2018

X Jennifer Rock

Jennifer Rock

Signed by: U0067718

Sworn by Jennifer Rock, West Publishing Corporation, 610 Opperman Drive, Eagan, MN 55123